Abstract
Patients with Mild Cognitive Impairment (MCI) not converted to dementia at one to three years follow-up represent an heterogeneous group across studies, by including ‘late converters’ but also patients without any neurodegenerative disease. We tested the hypothesis that the combination of memory and brain metabolic assessment could identify subgroups of memory decliners (MCI/Decl) and non-decliners (MCI/noDecl) before a long follow-up time is available. From twenty-nine patients with amnestic MCI (aMCI) at baseline, three groups were identified at follow-up: 10 patients who converted to AD (MCI/AD); 10 patients either showing episodic memory worsening or reaching the floor effect on memory and declining in other key tests (MCI/Decl) and 9 patients showing no memory worsening or even improvement (MCI/noDecl). They were compared with a group of fourteen elderly controls (CTR) by means of basal FDG-PET voxelbased analysis (SPM2). Two hypometabolic clusters were found in MCI/AD versus CTR, including the bilateral posterior cingulate cortex, the left parietal precuneus and the left fusiform gyrus. MCI/AD showed also a large hypometabolic region, mainly including the left medium and superior temporal gyri and inferior parietal lobule, when compared to MCI/noDecl. The MCI/Decl showed a hypometabolic region in the left medial temporal lobe versus both CTR (hippocampus) and MCI/noDecl (parahippocampal gyrus and hippocampus). No significant difference was found in the comparison between CTR and MCI/noDecl, neither in the comparison between MCI/Decl and MCI/AD. Thus, non converter MCI patients comprised a sub-group of ‘decliners’ with AD-like metabolic and cognitive patterns, likely including ‘late converters’, and a sub-group lacking this pattern, with stable or improving memory function and a brain metabolic picture similar to that in healthy controls. Combining neuropsychological and FDG-PET information could be used for prognostic purposes in aMCI patients at medium-term follow-up.
Keywords: FDG-PET, episodic memory, amnestic mild cognitive impairment, Alzheimer's disease
Current Alzheimer Research
Title: MCI Patients Declining and Not-Declining at Mid-Term Follow-Up: FDG-PET Findings
Volume: 7 Issue: 4
Author(s): M. Pagani, B. Dessi, S. Morbelli, A. Brugnolo, D. Salmaso, A. Piccini, D. Mazzei, G. Villavecchia, S.A. Larsson, G. Rodriguez and F. Nobili
Affiliation:
Keywords: FDG-PET, episodic memory, amnestic mild cognitive impairment, Alzheimer's disease
Abstract: Patients with Mild Cognitive Impairment (MCI) not converted to dementia at one to three years follow-up represent an heterogeneous group across studies, by including ‘late converters’ but also patients without any neurodegenerative disease. We tested the hypothesis that the combination of memory and brain metabolic assessment could identify subgroups of memory decliners (MCI/Decl) and non-decliners (MCI/noDecl) before a long follow-up time is available. From twenty-nine patients with amnestic MCI (aMCI) at baseline, three groups were identified at follow-up: 10 patients who converted to AD (MCI/AD); 10 patients either showing episodic memory worsening or reaching the floor effect on memory and declining in other key tests (MCI/Decl) and 9 patients showing no memory worsening or even improvement (MCI/noDecl). They were compared with a group of fourteen elderly controls (CTR) by means of basal FDG-PET voxelbased analysis (SPM2). Two hypometabolic clusters were found in MCI/AD versus CTR, including the bilateral posterior cingulate cortex, the left parietal precuneus and the left fusiform gyrus. MCI/AD showed also a large hypometabolic region, mainly including the left medium and superior temporal gyri and inferior parietal lobule, when compared to MCI/noDecl. The MCI/Decl showed a hypometabolic region in the left medial temporal lobe versus both CTR (hippocampus) and MCI/noDecl (parahippocampal gyrus and hippocampus). No significant difference was found in the comparison between CTR and MCI/noDecl, neither in the comparison between MCI/Decl and MCI/AD. Thus, non converter MCI patients comprised a sub-group of ‘decliners’ with AD-like metabolic and cognitive patterns, likely including ‘late converters’, and a sub-group lacking this pattern, with stable or improving memory function and a brain metabolic picture similar to that in healthy controls. Combining neuropsychological and FDG-PET information could be used for prognostic purposes in aMCI patients at medium-term follow-up.
Export Options
About this article
Cite this article as:
Pagani M., Dessi B., Morbelli S., Brugnolo A., Salmaso D., Piccini A., Mazzei D., Villavecchia G., Larsson S.A., Rodriguez G. and Nobili F., MCI Patients Declining and Not-Declining at Mid-Term Follow-Up: FDG-PET Findings, Current Alzheimer Research 2010; 7 (4) . https://dx.doi.org/10.2174/156720510791162368
DOI https://dx.doi.org/10.2174/156720510791162368 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension
Current Pharmaceutical Design Atrial Fibrillation: Epidemiology and Peculiarities in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Membrane Interactions of Oligomeric Alpha-Synuclein: Potential Role in Parkinsons Disease
Current Protein & Peptide Science An Introduction to Obesity and Dementia
Current Alzheimer Research Suicide and Suicide Attempts in Elderly Patients: An Epidemiological Analysis of Risk Factors and Prevention
Current Pharmaceutical Design Editorial [Hot Topic: QSAR Models for Computer-Aided Drug Design and Molecular Docking for Disorders of the Central Nervous System and Other Diseases]
Current Topics in Medicinal Chemistry Systematic Review Investigating Multi-disciplinary Team Approaches to Screening and Early Diagnosis of Dementia in Primary Care – What are the Positive and Negative Effects and Who Should Deliver It?
Current Alzheimer Research Early Features in Frontotemporal Dementia
Current Alzheimer Research One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study
Current Alzheimer Research Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Fused 1,4-Dihydropyridines as Potential Calcium Modulatory Compounds
Mini-Reviews in Medicinal Chemistry [<sup>18</sup>F]Amylovis as a Potential PET Probe for β-Amyloid Plaque: Synthesis, <i>In Silico, In vitro</i> and <i>In vivo</i> Evaluations
Current Radiopharmaceuticals Dementia from a Childs Perspective
Current Aging Science Genetic Variants and Oxidative Stress in Alzheimer’s Disease
Current Alzheimer Research The Pharmacological Management of Delirium in Critical Illness
Current Drug Therapy Diabetes and Parkinson’s Disease: Debating the Link Through Ca2+/cAMP Signalling
Current Diabetes Reviews ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Microbial Agents, Immune Function and Atheromatosis: The Chlamydophila pneumoniae Role
Current Immunology Reviews (Discontinued) Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry